PCK
vs
S
S&P/ASX 300
PCK
Over the past 12 months, PCK has underperformed S&P/ASX 300, delivering a return of -78% compared to S&P/ASX 300's +2% growth.
Stocks Performance
PCK vs S&P/ASX 300
Performance Gap
PCK vs S&P/ASX 300
Performance By Year
PCK vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
PainChek Ltd
Glance View
PainChek Ltd makes a smartphone-based software tool that helps caregivers assess pain in people who cannot clearly explain how they feel, such as older adults with dementia or people with disability. The app guides the user through a structured observation of facial expressions and other signs, then records the result in a simple digital format. Its main customers are aged care providers, disability care organizations, hospitals, and other healthcare groups that need a more consistent way to document pain. The company makes money mainly by selling access to its software, usually through subscriptions or licensing agreements. In practice, customers pay for the right to use the PainChek app and related clinical workflow tools across their care teams. That makes PainChek more like a healthcare software company than a drug or device maker: it earns recurring fees for an assessment tool that fits into everyday care routines. What makes the business different is that it sits at the point where clinical care meets digital documentation. Instead of replacing a nurse or caregiver, it gives them a standardized method to capture pain signals and share that information with clinicians and care managers. That puts PainChek in a niche but important role in healthcare, where better recordkeeping and earlier pain detection can improve day-to-day decisions for vulnerable patients.
